{"nctId":"NCT01892436","briefTitle":"Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis","startDateStruct":{"date":"2013-09-30","type":"ACTUAL"},"conditions":["Psoriatic Arthritis"],"count":460,"armGroups":[{"label":"Secukinumab 75mg","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]},{"label":"Secukinumab 150mg","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]},{"label":"Placebo - AIN457A 75mg","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab","Drug: Placebo"]},{"label":"Placebo - AIN457 150mg","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab","Drug: Placebo"]}],"interventions":[{"name":"Secukinumab","otherNames":["AIN457"]},{"name":"Placebo","otherNames":["Placebo - AIN457A"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed\n* Subjects must have participated in core study CAIN457F2306, and must have completed the entire treatment period\n* Subjects must be deemed by the investigator to benefit from continued secukinumab therapy\n\nExclusion criteria\n\n* Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab\n* Any subject who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., 20 weeks in EU)\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20","description":"Proportion of subjects with a positive clinical response to treatment (individual improvement) in disease activity according to ACR20 criteria if he/she has at least 20% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:\n\n* Patient's assessment of Psoriatic Arthritis (PsA) pain\n* Patient's global assessment of disease activity\n* Physician's global assessment of disease activity\n* Subject self-assessed disability (Health-Assessment Questionnaire \\[HAQ-DI\\] score)\n* Acute phase reactant (hsCRP or ESR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"73.9","spread":null},{"groupId":"OG002","value":"73.2","spread":null},{"groupId":"OG003","value":"73.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"72.9","spread":null},{"groupId":"OG002","value":"76.8","spread":null},{"groupId":"OG003","value":"74.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":null},{"groupId":"OG001","value":"71.1","spread":null},{"groupId":"OG002","value":"79.2","spread":null},{"groupId":"OG003","value":"69.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"76.1","spread":null},{"groupId":"OG002","value":"75.3","spread":null},{"groupId":"OG003","value":"67.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"72.5","spread":null},{"groupId":"OG002","value":"74.6","spread":null},{"groupId":"OG003","value":"67.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"66.9","spread":null},{"groupId":"OG002","value":"75.0","spread":null},{"groupId":"OG003","value":"68.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null},{"groupId":"OG001","value":"69.5","spread":null},{"groupId":"OG002","value":"83.3","spread":null},{"groupId":"OG003","value":"80.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"67.9","spread":null},{"groupId":"OG002","value":"78.8","spread":null},{"groupId":"OG003","value":"77.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Who Reached ACR50","description":"Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR50 criteria if he/she has at least 50% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:\n\n* Patient's assessment of PsA pain\n* Patient's global assessment of disease activity\n* Physician's global assessment of disease activity\n* Subject self-assessed disability (Health-Assessment Questionnaire \\[HAQ-DI\\] score)\n* Acute phase reactant (hsCRP or ESR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"51.0","spread":null},{"groupId":"OG002","value":"49.3","spread":null},{"groupId":"OG003","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"52.9","spread":null},{"groupId":"OG002","value":"56.5","spread":null},{"groupId":"OG003","value":"53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"48.7","spread":null},{"groupId":"OG002","value":"51.4","spread":null},{"groupId":"OG003","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":null},{"groupId":"OG001","value":"56.1","spread":null},{"groupId":"OG002","value":"52.1","spread":null},{"groupId":"OG003","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"52.2","spread":null},{"groupId":"OG003","value":"50.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null},{"groupId":"OG001","value":"46.9","spread":null},{"groupId":"OG002","value":"52.9","spread":null},{"groupId":"OG003","value":"53.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":null},{"groupId":"OG001","value":"53.4","spread":null},{"groupId":"OG002","value":"53.0","spread":null},{"groupId":"OG003","value":"50.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"52.7","spread":null},{"groupId":"OG002","value":"60.6","spread":null},{"groupId":"OG003","value":"50.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Who Reached ACR70","description":"Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR70 criteria if he/she has at least 70% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:- Patient's assessment of PsA pain\n\n* Patient's global assessment of disease activity\n* Physician's global assessment of disease activity\n* Subject self-assessed disability (Health-Assessment Questionnaire \\[HAQ-DI\\] score)\n* Acute phase reactant (hsCRP or ESR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"30.1","spread":null},{"groupId":"OG002","value":"28.2","spread":null},{"groupId":"OG003","value":"29.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"31.0","spread":null},{"groupId":"OG002","value":"34.8","spread":null},{"groupId":"OG003","value":"23.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"28.3","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"26.0","spread":null},{"groupId":"OG003","value":"27.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"31.2","spread":null},{"groupId":"OG002","value":"31.3","spread":null},{"groupId":"OG003","value":"27.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"31.0","spread":null},{"groupId":"OG002","value":"32.4","spread":null},{"groupId":"OG003","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"32.1","spread":null},{"groupId":"OG002","value":"37.9","spread":null},{"groupId":"OG003","value":"34.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"37.4","spread":null},{"groupId":"OG002","value":"37.9","spread":null},{"groupId":"OG003","value":"33.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)","description":"Changes from baseline in score of the disability assessment component of the HAQ (Health Assessment Questionnaire - Disability Index). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.\n\nHealth Assessment Questionnaire - Disability Index (HAQ-DI) ranges from 0 (no disability) to 3 (very severe disability)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4537","spread":"0.60617"},{"groupId":"OG001","value":"-0.4592","spread":"0.56155"},{"groupId":"OG002","value":"-0.5642","spread":"0.56722"},{"groupId":"OG003","value":"-0.4115","spread":"0.66721"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4171","spread":"0.61192"},{"groupId":"OG001","value":"-0.4619","spread":"0.55835"},{"groupId":"OG002","value":"-0.5143","spread":"0.55599"},{"groupId":"OG003","value":"-0.3750","spread":"0.69661"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4448","spread":"0.61406"},{"groupId":"OG001","value":"-0.4713","spread":"0.58791"},{"groupId":"OG002","value":"-0.4635","spread":"0.56037"},{"groupId":"OG003","value":"-0.3507","spread":"0.69221"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4236","spread":"0.61896"},{"groupId":"OG001","value":"-0.4266","spread":"0.57491"},{"groupId":"OG002","value":"-0.5068","spread":"0.62548"},{"groupId":"OG003","value":"-0.3159","spread":"0.73507"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4617","spread":"0.61472"},{"groupId":"OG001","value":"-0.4305","spread":"0.59901"},{"groupId":"OG002","value":"-0.5698","spread":"0.65258"},{"groupId":"OG003","value":"-0.3538","spread":"0.71246"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4463","spread":"0.57130"},{"groupId":"OG001","value":"-0.3857","spread":"0.59304"},{"groupId":"OG002","value":"-0.5531","spread":"0.62622"},{"groupId":"OG003","value":"-0.3447","spread":"0.74745"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4710","spread":"0.60931"},{"groupId":"OG001","value":"-0.4122","spread":"0.60461"},{"groupId":"OG002","value":"-0.5777","spread":"0.66930"},{"groupId":"OG003","value":"-0.3952","spread":"0.72115"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4821","spread":"0.61170"},{"groupId":"OG001","value":"-0.4036","spread":"0.58334"},{"groupId":"OG002","value":"-0.5038","spread":"0.61039"},{"groupId":"OG003","value":"-0.3730","spread":"0.71306"}]}]}]},{"type":"SECONDARY","title":"Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)","description":"Percentage of subjects with improvements from baseline in HAQ-DI meeting or exceeding minimal clinically important difference (MCID=0.3). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"52.3","spread":null},{"groupId":"OG002","value":"63.9","spread":null},{"groupId":"OG003","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8","spread":null},{"groupId":"OG001","value":"51.9","spread":null},{"groupId":"OG002","value":"57.1","spread":null},{"groupId":"OG003","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"52.3","spread":null},{"groupId":"OG002","value":"56.9","spread":null},{"groupId":"OG003","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8","spread":null},{"groupId":"OG001","value":"52.3","spread":null},{"groupId":"OG002","value":"60.8","spread":null},{"groupId":"OG003","value":"44.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null},{"groupId":"OG001","value":"51.5","spread":null},{"groupId":"OG002","value":"61.2","spread":null},{"groupId":"OG003","value":"47.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"59.4","spread":null},{"groupId":"OG003","value":"48.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"48.9","spread":null},{"groupId":"OG002","value":"59.1","spread":null},{"groupId":"OG003","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"48.9","spread":null},{"groupId":"OG002","value":"59.1","spread":null},{"groupId":"OG003","value":"53.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Score-CRP (DAS28)","description":"Changes in DAS28 (utilizing hsCRP) from baseline up to Month 60. The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. This measure represents change in scores - not the actual scores.\n\nDAS28 is a combined measure of disease activity based on the following formula:\n\nDAS28-CRP = 0.56\\*TJC28\\^0.5 + 0.28\\*SJC28\\^0.5 + 0.36\\*ln(CRP+1) + 0.014\\*PGA + 0.96 The greater the score is, the more the disease activity exists. Remission is defined as DAS28-CRP \\< 2.6 Low disease activity is defined as DAS28-CRP \\< 3.2 The minimum value can be 0.96 (not applicable in our study due to the inclusion/exclusion criteria regarding tender, swollen joints). There is no maximum expected value for this score","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.044","spread":"1.3382"},{"groupId":"OG001","value":"-1.904","spread":"1.3165"},{"groupId":"OG002","value":"-2.282","spread":"1.2732"},{"groupId":"OG003","value":"-1.853","spread":"1.2737"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.013","spread":"1.3446"},{"groupId":"OG001","value":"-1.962","spread":"1.2900"},{"groupId":"OG002","value":"-2.333","spread":"1.2815"},{"groupId":"OG003","value":"-2.031","spread":"1.3290"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.074","spread":"1.3224"},{"groupId":"OG001","value":"-1.912","spread":"1.2246"},{"groupId":"OG002","value":"-2.412","spread":"1.3059"},{"groupId":"OG003","value":"-1.830","spread":"1.3136"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.844","spread":"1.4923"},{"groupId":"OG001","value":"-1.942","spread":"1.3195"},{"groupId":"OG002","value":"-2.109","spread":"1.3188"},{"groupId":"OG003","value":"-1.743","spread":"1.3630"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.058","spread":"1.3760"},{"groupId":"OG001","value":"-1.937","spread":"1.2674"},{"groupId":"OG002","value":"-2.327","spread":"1.2339"},{"groupId":"OG003","value":"-1.867","spread":"1.4590"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.042","spread":"1.2907"},{"groupId":"OG001","value":"-1.767","spread":"1.4574"},{"groupId":"OG002","value":"-2.344","spread":"1.3351"},{"groupId":"OG003","value":"-1.862","spread":"1.4708"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.225","spread":"1.2570"},{"groupId":"OG001","value":"-2.046","spread":"1.2590"},{"groupId":"OG002","value":"-2.611","spread":"1.3247"},{"groupId":"OG003","value":"-2.286","spread":"1.2102"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.112","spread":"1.2664"},{"groupId":"OG001","value":"-2.074","spread":"1.3146"},{"groupId":"OG002","value":"-2.506","spread":"1.3774"},{"groupId":"OG003","value":"-2.099","spread":"1.2466"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Low Disease Activity","description":"Percentage of subjects achieving low disease activity (DAS28 â‰¤ 3.2). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"64.7","spread":null},{"groupId":"OG002","value":"70.4","spread":null},{"groupId":"OG003","value":"63.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null},{"groupId":"OG001","value":"69.9","spread":null},{"groupId":"OG002","value":"75.4","spread":null},{"groupId":"OG003","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"66.0","spread":null},{"groupId":"OG002","value":"75.0","spread":null},{"groupId":"OG003","value":"65.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4","spread":null},{"groupId":"OG001","value":"67.9","spread":null},{"groupId":"OG002","value":"61.6","spread":null},{"groupId":"OG003","value":"58.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null},{"groupId":"OG001","value":"70.1","spread":null},{"groupId":"OG002","value":"65.7","spread":null},{"groupId":"OG003","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":null},{"groupId":"OG001","value":"65.8","spread":null},{"groupId":"OG002","value":"67.2","spread":null},{"groupId":"OG003","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null},{"groupId":"OG001","value":"73.5","spread":null},{"groupId":"OG002","value":"79.4","spread":null},{"groupId":"OG003","value":"84.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"76.9","spread":null},{"groupId":"OG003","value":"77.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Disease Remission (DAS28<2.6)","description":"Percentage of subjects achieving disease remission (DAS28\\<2.6). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"50.3","spread":null},{"groupId":"OG002","value":"47.9","spread":null},{"groupId":"OG003","value":"45.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6","spread":null},{"groupId":"OG001","value":"49.4","spread":null},{"groupId":"OG002","value":"55.1","spread":null},{"groupId":"OG003","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","spread":null},{"groupId":"OG001","value":"46.7","spread":null},{"groupId":"OG002","value":"55.6","spread":null},{"groupId":"OG003","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null},{"groupId":"OG001","value":"52.6","spread":null},{"groupId":"OG002","value":"43.8","spread":null},{"groupId":"OG003","value":"46.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"53.3","spread":null},{"groupId":"OG002","value":"49.3","spread":null},{"groupId":"OG003","value":"58.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"52.1","spread":null},{"groupId":"OG002","value":"55.2","spread":null},{"groupId":"OG003","value":"53.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"61.4","spread":null},{"groupId":"OG002","value":"65.1","spread":null},{"groupId":"OG003","value":"69.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"58.3","spread":null},{"groupId":"OG002","value":"64.6","spread":null},{"groupId":"OG003","value":"66.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":48,"n":292},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Bronchitis","Hypertension"]}}}